Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
David M. Epstein
|
| gptkbp:clinicalTrialPhase |
Phase 1
|
| gptkbp:developedBy |
small molecule drugs
|
| gptkbp:focusesOn |
precision oncology
|
| gptkbp:foundedYear |
2014
|
| gptkbp:founder |
gptkb:Elizabeth_Buck
David M. Epstein |
| gptkbp:hasCompany |
true
|
| gptkbp:headquartersLocation |
gptkb:Cambridge,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Black Diamond Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:listedOn |
gptkb:NASDAQ
|
| gptkbp:notableProduct |
BDTX-1535
BDTX-4933 |
| gptkbp:numberOfEmployees |
approximately 70 (as of 2023)
|
| gptkbp:platform |
Mutation-Allostery-Pharmacology (MAP) platform
|
| gptkbp:specializesIn |
targeted cancer therapies
|
| gptkbp:stockSymbol |
BDTX
|
| gptkbp:target |
oncogenic driver mutations
|
| gptkbp:website |
https://www.blackdiamondtherapeutics.com/
|
| gptkbp:bfsParent |
gptkb:Versant_Ventures
|
| gptkbp:bfsLayer |
7
|